Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IceCure Medical (ICCM) Other financing activities (2020 - 2025)

Historic Other financing activities for IceCure Medical (ICCM) over the last 6 years, with Q3 2025 value amounting to $125.5 million.

  • IceCure Medical's Other financing activities rose 1310.02% to $125.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $125.5 million, marking a year-over-year increase of 1310.02%. This contributed to the annual value of $112.3 million for FY2024, which is 983.72% up from last year.
  • Latest data reveals that IceCure Medical reported Other financing activities of $125.5 million as of Q3 2025, which was up 1310.02% from $115.2 million recorded in Q2 2025.
  • IceCure Medical's Other financing activities' 5-year high stood at $100.8 billion during Q4 2022, with a 5-year trough of $69.0 million in Q2 2021.
  • Over the past 5 years, IceCure Medical's median Other financing activities value was $102.0 million (recorded in 2023), while the average stood at $5.7 billion.
  • Per our database at Business Quant, IceCure Medical's Other financing activities soared by 11798429.66% in 2022 and then plummeted by 9989.86% in 2023.
  • IceCure Medical's Other financing activities (Quarter) stood at $85.4 million in 2021, then skyrocketed by 117984.3% to $100.8 billion in 2022, then plummeted by 99.9% to $102.2 million in 2023, then increased by 9.84% to $112.3 million in 2024, then increased by 11.77% to $125.5 million in 2025.
  • Its Other financing activities was $125.5 million in Q3 2025, compared to $115.2 million in Q2 2025 and $115.0 million in Q1 2025.